X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1748) 1748
Publication (70) 70
Patent (41) 41
Book Chapter (30) 30
Conference Proceeding (12) 12
Book Review (8) 8
Book / eBook (7) 7
Web Resource (5) 5
Newsletter (4) 4
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (930) 930
hematology (737) 737
male (492) 492
female (491) 491
index medicus (485) 485
middle aged (449) 449
aged (400) 400
oncology (400) 400
adult (364) 364
prognosis (250) 250
aged, 80 and over (230) 230
mutation (229) 229
myelofibrosis (202) 202
polycythemia-vera (194) 194
essential thrombocythemia (165) 165
leukemia (159) 159
risk factors (149) 149
myeloproliferative disorders (146) 146
janus kinase 2 - genetics (145) 145
diagnosis (143) 143
medicine, general & internal (142) 142
adolescent (126) 126
research (126) 126
treatment outcome (126) 126
genetic aspects (118) 118
primary myelofibrosis - genetics (114) 114
retrospective studies (100) 100
survival (100) 100
jak2 (93) 93
myeloproliferative neoplasms (93) 93
myelodysplastic syndromes (92) 92
myeloid metaplasia (84) 84
abridged index medicus (83) 83
myeloproliferative disorders - genetics (83) 83
therapy (83) 83
acute myeloid-leukemia (82) 82
care and treatment (79) 79
survival analysis (79) 79
survival rate (76) 76
gene mutations (75) 75
primary myelofibrosis - drug therapy (75) 75
young adult (75) 75
bone marrow - pathology (70) 70
chronic myelomonocytic leukemia (70) 70
health aspects (70) 70
primary myelofibrosis - pathology (70) 70
idiopathic myelofibrosis (69) 69
primary myelofibrosis - mortality (69) 69
primary myelofibrosis - complications (68) 68
primary myelofibrosis - diagnosis (67) 67
polycythemia (66) 66
follow-up studies (63) 63
disease progression (61) 61
mutations (61) 61
world-health-organization (61) 61
diagnosis, differential (60) 60
chronic myelogenous leukemia (59) 59
primary myelofibrosis (58) 58
antineoplastic agents - therapeutic use (57) 57
bone marrow (56) 56
cancer (56) 56
stem-cell transplantation (56) 56
primary myelofibrosis - therapy (55) 55
myelodysplastic syndromes - genetics (54) 54
classification (53) 53
cohort studies (52) 52
polycythemia vera - genetics (52) 52
polycythemia vera (51) 51
polycythemia vera - diagnosis (50) 50
thrombocythemia, essential - diagnosis (49) 49
transplantation (49) 49
analysis (48) 48
chronic myeloid-leukemia (48) 48
international working group (47) 47
tyrosine kinase jak2 (47) 47
chronic myeloproliferative disorders (46) 46
anemia (45) 45
bone-marrow (45) 45
imatinib mesylate (45) 45
disease-free survival (44) 44
risk (44) 44
scoring system (44) 44
karyotyping (43) 43
myelodysplastic syndrome (43) 43
myeloproliferative disorders - diagnosis (43) 43
neoplasms (43) 43
splenectomy (43) 43
myeloproliferative (42) 42
prognostic scoring system (41) 41
thrombosis (41) 41
animals (40) 40
disorders (40) 40
human necessities (40) 40
thrombocythemia, essential - genetics (40) 40
agnogenic myeloid metaplasia (39) 39
dna mutational analysis (39) 39
hygiene (39) 39
janus kinase 2 (39) 39
medical or veterinary science (39) 39
phenotype (39) 39
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1831) 1831
French (13) 13
German (8) 8
Spanish (7) 7
Portuguese (3) 3
Chinese (2) 2
Korean (2) 2
Croatian (1) 1
Danish (1) 1
Lithuanian (1) 1
Polish (1) 1
Russian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 12, pp. 2721 - 2730
Journal Article
American Journal of Hematology, ISSN 0361-8609, 12/2016, Volume 91, Issue 12, pp. 1262 - 1271
Journal Article
American Journal of Hematology, ISSN 0361-8609, 03/2012, Volume 87, Issue 3, pp. 284 - 293
Disease overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms primarily characterized by erythrocytosis and... 
ACUTE-LEUKEMIA | JAK2(V617F) MUTATION | VONWILLEBRAND-FACTOR | PRIMARY PROLIFERATIVE POLYCYTHEMIA | LOW-DOSE ASPIRIN | MYELOPROLIFERATIVE DISORDERS | PROGNOSTIC-FACTORS | PLATELET ACTIVATION | HEMATOLOGY | VON-WILLEBRAND-FACTOR | WORLD-HEALTH-ORGANIZATION | Age Factors | Humans | Polycythemia Vera - blood | Polycythemia Vera - genetics | Alkylating Agents - adverse effects | Thrombophilia - epidemiology | Alkylating Agents - therapeutic use | Polycythemia Vera - epidemiology | Thrombophilia - etiology | DNA Mutational Analysis | Aspirin - therapeutic use | Leukocyte Count | Thrombosis - prevention & control | Thrombophilia - drug therapy | Leukemia, Myeloid - epidemiology | Acute Disease | Randomized Controlled Trials as Topic - statistics & numerical data | Busulfan - adverse effects | Busulfan - therapeutic use | Risk Assessment | Interferon-alpha - therapeutic use | Janus Kinase 2 - genetics | Phlebotomy | Anticoagulants - therapeutic use | Thrombosis - epidemiology | Polycythemia Vera - therapy | Thrombocythemia, Essential - blood | Polycythemia Vera - diagnosis | Disease Progression | Leukemia, Myeloid - etiology | Hydroxyurea - adverse effects | Thrombocythemia, Essential - diagnosis | Thrombocythemia, Essential - epidemiology | Survival Analysis | Thrombocythemia, Essential - therapy | Hydroxyurea - therapeutic use | Disease Management
Journal Article